Articles

Clopidogrel Prasugrel TCT 2012 Smoking PARADOX Study Antiplatelet Therapy

Results of a study investigating the effects of smoking on the antiplatelet medications clopidogrel and prasugrel were presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT)...

A large observational study found the increased risk associated with dual antiplatelet therapy cessation after percutaneous coronary intervention (PCI) is tied to patient non-adherence, as opposed...

Boston Scientific Renal Denervation Vessix Vascular

November 8, 2012 — Boston Scientific Corp. is extending its reach into the renal denervation market by signing a...

November 7, 2012 — Kona Medical Inc. announced the initiation of the first clinical study of its device...

ADAPT-DES study TCT, 2012, Plavix, stent

November 2, 2012 — Patients who receive a drug-eluting stent (DES) and demonstrate low levels of platelet inhibition are more likely to have blood clots form on the stent and suffer a possible...

September 7, 2012 — St. Jude Medical Inc. announced results of the FAME II trial demonstrating that patients with...

Verifynow platelet testing clopidogrel nonresponders

Patients with 2C19 that is less active due to loss of gene copies are poor metabolizers of clopidogrel, opening patients to the possibility of a higher rate of mayocardial infacrtion (...

The standard-of-care for dual antiplatelet therapy (DAPT) for more than a decade has been clopidogrel (Plavix) plus aspirin. This standard is now being challenged by new agents —...

August 23, 2012 — Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, finds that the 12-month post-hospital acute coronary syndrome market will initially...